Compare Abeona Therapeutics Inc (ABEO) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Tencent Music Entertainment Group - ADR trades at $8.83 (market cap $14.27B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 38.2× Abeona Therapeutics Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.78% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TME | |
|---|---|---|
Market Cap | $373.32M | $14.27B |
Sector | Health | Media |
52-Week High | $7.23 | $26.36 |
52-Week Low | $4.17 | $8.16 |
Enterprise Value | $228.22M | $11.05B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TME trades at $8.62, showing slight daily weakness. The stock presents a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported strong revenue growth to $32.90B in 2025 with a robust net income margin of 26.48%, though recent quarterly earnings have missed expectations. Analyst sentiment is divided with a consensus price target of $14.00, representing significant upside potential from current levels.
The investment case for TME hinges on its solid profitability and reasonable valuation multiples, but faces headwinds from competitive pressures and recent earnings misses. Key risks include intensifying competition in China's music streaming market and potential regulatory scrutiny. The consensus view suggests moderate bullishness with the stock trading below analyst targets, though execution on growth initiatives remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
